Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
190.60
-2.37 (-1.23%)
Official Closing Price
Updated: 7:00 PM EST, Feb 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
January 31, 2025
US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings.
Via
Benzinga
Earnings Scheduled For January 31, 2025
January 31, 2025
Via
Benzinga
$100 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
January 30, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On AbbVie Through 15 Analysts
January 28, 2025
Via
Benzinga
$1000 Invested In AbbVie 5 Years Ago Would Be Worth This Much Today
January 24, 2025
Via
Benzinga
Unpacking the Latest Options Trading Trends in AbbVie
January 24, 2025
Via
Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
January 30, 2025
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
Via
Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
January 29, 2025
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
Via
Benzinga
Topics
Government
Exposures
Political
I Own 4 High-Yield Dividend Stocks. Here's Why I Own Each One.
January 28, 2025
Via
The Motley Fool
Why AbbVie Stock Popped While the Market Flopped on Monday
January 27, 2025
Via
The Motley Fool
AbbVie Unusual Options Activity For January 10
January 10, 2025
Via
Benzinga
Assessing AbbVie: Insights From 17 Financial Analysts
January 08, 2025
Via
Benzinga
AbbVie Builds Momentum With Immunology Growth, Goldman Remains Positive
January 27, 2025
AbbVie plans to release Q4 2024 results on Jan. 31. Analysts predict $14.8 billion in sales, $2.10 EPS. Immunology growth remains a key focus for investors.
Via
Benzinga
Biotech And Healthcare Stocks Poised For Gains Ahead
January 27, 2025
The XLV bounced off the bottom this month up 4% to the $144 level led by biopharma and medtech.
Via
Talk Markets
Topics
ETFs
Stocks / Equities
Is AbbVie Stock a Buy?
January 24, 2025
Although AbbVie has lost patent exclusivity for its flagship drug, Humira, the company may soon be bigger and better.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
January 21, 2025
Via
The Motley Fool
Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere — Here's Why
January 21, 2025
The company expects to soon expand from a single-product player to a "multi-product innovator."
Via
Investor's Business Daily
Got $500? 2 Pharmaceutical Stocks to Buy and Hold Forever
January 21, 2025
Via
The Motley Fool
3 Unstoppable Dividend-Growth Stocks Yielding More Than 3% That Income-Seeking Investors Want to Buy in 2025 and Hold Forever
January 21, 2025
Via
The Motley Fool
Healthcare And Biotech Stocks Lag The Market Again
January 20, 2025
Biotech stocks got little help from the JPM Conference despite some recovery to the general market.
Via
Talk Markets
Topics
Stocks / Equities
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
January 17, 2025
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company.
Via
Benzinga
Topics
Government
Exposures
Political
Popular Ozempic, Wegovy Selected For Next Round Of Medicare Drug Price Negotiations
January 17, 2025
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Top Research Reports For Visa, AbbVie & Analog Devices
January 15, 2025
Today's Research Daily features new research reports on 16 major stocks, including Visa Inc., AbbVie Inc., Analog Devices, Inc. (ADI), and a micro-cap stock Precipio, Inc.
Via
Talk Markets
Topics
Stocks / Equities
10 One Decision Stocks To Buy Now
January 15, 2025
The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats.
Via
Talk Markets
Topics
Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
January 14, 2025
Via
Benzinga
2 Brilliant Dividend Growth Stocks That Can Supercharge Your Portfolio
January 14, 2025
Via
The Motley Fool
3 High-Yielding Dividend Stocks That Could Be Ideal Investments for Retirees
January 14, 2025
Via
The Motley Fool
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
January 13, 2025
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline.
Via
Benzinga
3 High-Yield Dividend Stocks to Buy in 2025
January 13, 2025
Via
The Motley Fool
3 Incredible Dividend Stocks to Buy in 2025
January 11, 2025
These wildly successful companies are poised to keep your dividend portfolio healthy in 2025 and beyond.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
74
75
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.